Efficacy And Safety Of Tezepelumab In Adults With Severe, Uncontrolled Asthma In Asia: Results From The Regional, Phase 3 DIRECTION Study

被引：0

作者：

Yan, Yang ^{[1
]}

Wang, Lihong ^{[2
]}

Huang, Kewu ^{[3
,4
]}

Tang, Wei ^{[5
]}

Berame, Eli ^{[6
]}

Park, Haesim ^{[7
]}

Hunter, Gillian ^{[8
]}

Jiang, Wei ^{[9
]}

Wu, Chengyi ^{[10
]}

Min, Chiju ^{[9
]}

Domek-Lopacinska, Katarzyna ^{[11
]}

Lal, Harbans

Molfino, Nestor ^{[12
]}

Ponnarambil, Sandhia ^{[8
]}

Zhong, Nanshan ^{[1
]}

机构：

[1] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Peoples R China

[2] Inner Mongolia Med Univ, Affiliated Hosp, Hohhot, Peoples R China

[3] Capital Med Univ, Beijing Inst Resp Med, Beijing, Peoples R China

[4] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China

[5] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept PCCM, Shanghai, Peoples R China

[6] Healthlink Med Surg Dent Clin & Diagnost Ctr, Iloilo, Philippines

[7] Ajou Univ, Sch Med, Suwon, South Korea

[8] AstraZeneca, Cambridge, England

[9] AstraZeneca, Shanghai, Peoples R China

[10] AstraZeneca R&D, Shanghai, Peoples R China

[11] AstraZeneca, Warsaw, Poland

[12] Amgen Inc, Thousand Oaks, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

731

引用

页数：1